Journal of Clinical & Experimental Dermatology Research
Open Access

Brent J Doolan

Publications

• Case Report
  Cutaneous Lichen Planus Induced by Secukinumab
  Author(s): Brent J Doolan, Holly Anderton, Michael Christie and Con DolianitisBrent J Doolan, Holly Anderton, Michael Christie and Con Dolianitis
  
  Lichen planus (LP) is a chronic mucocutaneous disease, characterised by an inflammatory immune response with sub-epithelial infiltration of T lymphocytes causing basal epithelial cell damage. Secukinumab is a monoclonal antibody that blocks IL-17A; which is the primary cytokine of Th17 cells involved in the aetiology of inflammatory skin diseases such as psoriasis. Secukinumab has been linked to induction of oral LP, but never directly to cutaneous LP. We report the first case of drug-induced cutaneous LP in the setting of secukinumab for treatment of chronic plaque psoriasis. A 56-year-old man with chronic plaque psoriasis presented with a 2-month history of violaceous and pruritic, thickened plaques on his bilateral lower limbs and buttocks in the setting of secukinumab use for psoriasis. Histological analysis showed a band-like lymphocyte inflammatory infiltrate just beneath the ep.. View More»
  DOI: 10.4172/2155-9554.1000437

  Abstract PDF

Relevant Topics